PROTOCOL

TITLE:	**TEST**
PROTOCOL NUMBER:	XX12346
VERSION NUMBER:	**2.1**
EUDRACT NUMBER:	2017-000123-12
IND NUMBER:	123459
NCT NUMBER:	To be determined

TABLE OF CONTENTS

1. BACKGROUND

1.1 Test

1.2

2. OBJECTIVES AND ENDPOINTS

2.1 SAFTEY OBJECTIVES

2.2 EFFICACY OBJECTIVES

3. STUDY DESIGN

3.1 PATIENTS

Test

Aaaa

Bbbb

Xx

Yy

Zz

Responses will be recorded as successful if the patient or subject identifies the correct response per information in the accompanying IFU (and QRG, as applicable).

4. MATERIALS AND METHODS

4.1 PATIENTS AND SUBJECTS

The patients and subjects recruited for this study are intended to represent the user population with regard to characteristics and attributes that affect usability.

In this RLHF study, adult patients ≥18 years of age with RA who have been receiving SC TCZ q2w or qw with the use of the commercially available PFS-NSD will be enrolled. Patients should be suitable to continue receiving SC TCZ, and the self-injection group should be suitable candidates for use of an AI device. Patients will take part in the study in 1 of 3 groups as described in Section 3.1:

- Self-injecting patients
- Patients who receive injections from a CG
- Patients who receive injections from an HCP

Recruitment is anticipated at 1 to approximately 4 sites in the United States in order to recruit sufficient numbers of patients, CGs, and HCPs suitable for study participation.

At least 45 patients and 30 subjects will be recruited as follows:

- 15 self-injecting patients
- 15 patients and 15 CGs (patients in this group should be injected by their CG)
- 15 patients and 15 HCPs (patients in this group will be injected by an HCP).

Patients, CGs, and HCPs will be screened for suitability and consented.

At least 3 additional participants (1 patient, 1 CG, and 1 HCP) per site may be recruited and enrolled to participate in a pilot study conducted approximately 2 weeks prior to the start of formal data collection. Patients and subjects who participate in the pilot study will not participate to the main study; and they may not need to meet all the inclusion/exclusion criteria since the purpose of the pilot study is to test the study procedure and patients will not receive any injections of study drug.

4.1.1 Inclusion Criteria

All patients and subjects will be willing to commit to training and data collection that includes video recording, which may be used for educational and promotional purposes.

To be enrolled in the study, participants must meet the following criteria described in Sections 4.1.1.1 (patients), 4.1.1.2 (CG), and 4.1.1.3 (HCP).

4.1.1.1 Patients

- Able to give informed consent and willing to comply with the requirements of the study protocol
- Age≥ 18 years
- Be a current resident within the United States
- Have had RA for≥ 6 months, as diagnosed by a qualified rheumatologist, according to the revised 1987 American College of Rheumatology (ACR) criteria
  (Arnett et al. 1988)
- Patients must be deemed suitable candidates to use an AI at home, in the investigator's judgment, either by self-administration or from a CG or from a HCP
- Have been receiving 162 mg TCZ SC q2w or qw using the commercially

available PFS-NSD for at least 8 weeks, and are suitable for continued treatment with 162 mg TCZ SC at their currently prescribed dose

- Most recent laboratory results performed in accordance with the current Actemra U.S. Prescribing Information (USPI) do not warrant dose adjustment or discontinuation of therapy during the study period.
- At least 2 self-injecting patients will be left-hand dominant
- To continue using contraception as discussed with the patient's rheumatologist at the time of prescription of TCZ SC PFS-NSD

4.1.1.2 Caregivers

CGs may be already acquainted with (and already supporting) a specific patient enrolled in the study. So as to keep a realistic usage scenario, the CG may be paired with that patient for the duration of the study.

- Able to give informed consent and willing to comply with the requirements of the study protocol
- Age≥ 18 years
- Not professionally qualified to give an injection (e.g., a patient's spouse, relative).
- Able (after training) and willing to inject a patient at each visit
- Must be current resident within the United States

4.1.1.3 Healthcare Professionals

An HCP may be already acquainted with (and already supporting) a specific patient enrolled in the study. In those cases the HCP may be paired with that patient for the study duration.

- Able to give informed consent and willing to comply with the requirements of the study protocol
- Age≥ 18 years
- Must be current resident of the United States
- Professionally qualified to give an injection and willing to inject a patient and comply with the study protocol

4.1.2 Exclusion Criteria

4.1.2.1 Patients

Patients who meet any of the following criteria will be excluded from study entry:

- Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation

in and completion of the study, including but not limited to serious hypersensitivity or anaphylaxis to a previous SC injection or IV infusion of TCZ, current serious infection, opportunistic infection or sepsis, current active hepatic disease, or hepatic impairment

- Patients with functional RA status class IV (according to the 1991 ACR revised criteria for the classification of global functional status in RA [Hochberg et al. 1992]), as assessed by a rheumatologist at the screening visit.
- Neuropathies or other conditions that might interfere with pain evaluation
- Current participation in any interventional clinical trial
- Patients who self-report to be pregnant or nursing (breastfeeding)
- Patient or anyone in his/her immediate household is employed in the pharmaceutical industry
- Patient employed by Roche, Genentech, Battelle, or a contract research organization (CRO) involved in this study (WA29917)
- Participation in any previous Actemra research study that involved an AI.
- Prior use of the AI-1000 G1 or AI-1000 G2 in any HF study.
- ANC $< 1.0 \times 10^9$/L (1000/mm^3) at last (as per the USPI) laboratory assessment.
- Platelet count $< 100 \times 10^9$/L (100,000/mm^3) at last laboratory assessment.
- ALT or AST > upper limit of normal [ULN] at last laboratory assessment.

4.1.2.2 Caregivers

CGs who meet any of the following criteria will be excluded from study entry:

- Current participation in any interventional clinical trial
- Subject or anyone in his/her immediate household is employed in the pharmaceutical industry
- Subject employed by Roche, Genentech, Battelle, or a CRO involved in this study (WA29917)

4.1.2.3 Healthcare Professionals

HCPs who meet any of the following criteria will be excluded from study entry:

- Current participation in any interventional clinical trial as a patient
- Participation in the conduct or oversight of this study (WA29917)
- Subject or anyone in his/her immediate household is employed in the pharmaceutical industry.
- Subject employed by Roche, Genentech, Battelle or a CRO involved in this study (WA29917)

- Not professionally qualified to give injections

4.2 METHOD OF TREATMENT ASSIGNMENT AND BLINDING

Patients will take part in the study in one of three groups:

- Self-injecting patients
- Patients who receive injections from a CG
- Patients who receive injections from an HCP

A minimum of 15 patients and/or subjects are required per group, and patients may be assigned so that all groups have the required numbers.

4.3 STUDY TREATMENT